Brief: Oragenics Extends Collaboration With National Research Council Of Canada To Develop Vaccine Against Omicron Variant
20/12/2021 13:30
Dec 20 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS EXTENDS COLLABORATION WITH NATIONAL RESEARCH
COUNCIL
OF CANADA TO DEVELOP VACCINE AGAINST OMICRON VARIANT
* ORAGENICS - AGREEMENT EXTENDS CURRENT LICENSING &
COLLABORATION
AGREEMENT TO INCLUDE RAPID PRODUCTION OF OMICRON-SPECIFIC
INTRANASAL VACCINE CANDIDATES
* ORAGENICS INC - AGREEMENT WILL ENABLE CO TO PURSUE AN
INTRANASAL
VACCINE DESIGNED TO PROTECT AGAINST SARS-COV-2 OMICRON VARIANT
Source text for Eikon: ID:nBwc8y1Zja
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing